Errors in Figure 4 and Incorrect DNA Sequencing Manufacturer

No authors listed

Published Erratum

No authors listed. JAMA Oncol. 2024.

. 2024 Jul 1;10(7):989.

doi: 10.1001/jamaoncol.2024.3204.

No abstract available

Erratum for

Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Rosenberg AJ, Agrawal N, Juloori A, Cursio J, Gooi Z, Blair E, Chin J, Ginat D, Pasternak-Wise O, Hasina R, Starus A, Jones FS, Izumchenko E, MacCracken E, Wolk R, Cipriani N, Lingen MW, Pearson AT, Seiwert TY, Haraf DJ, Vokes EE. Rosenberg AJ, et al. JAMA Oncol. 2024 Jul 1;10(7):923-931. doi: 10.1001/jamaoncol.2024.1530. JAMA Oncol. 2024. PMID: 38842838 Free PMC article. Clinical Trial.

1. Rosenberg AJ, Agrawal N, Juloori A, et al. . Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized clinical trial. JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.1530 - DOI - PMC - PubMed